News stories about Galmed Pharmaceuticals (NASDAQ:GLMD) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galmed Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.6582179142007 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Zacks Investment Research Downgrades Galmed Pharmaceuticals (GLMD) to Hold (americanbankingnews.com)
- Galmed Pharmaceuticals (GLMD) Given a $14.00 Price Target at Maxim Group (americanbankingnews.com)
- Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering (finance.yahoo.com)
- Galmed Pharmaceuticals (GLMD) Upgraded at ValuEngine (americanbankingnews.com)
A number of research analysts have commented on the stock. Maxim Group set a $14.00 price objective on shares of Galmed Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, April 3rd. ValuEngine upgraded shares of Galmed Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, April 3rd. Finally, Zacks Investment Research lowered shares of Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $20.40.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Galmed Pharmaceuticals had a negative return on equity of 133.50% and a negative net margin of 1,133.55%. The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. research analysts anticipate that Galmed Pharmaceuticals will post -0.77 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3343574/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-galmed-pharmaceuticals-glmd-stock-price.html.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.